179 related articles for article (PubMed ID: 31894239)
21. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
Detlefsen AJ; Mesaros CA; Duan L; Penning TM
Cancer Res Commun; 2023 Sep; 3(9):1888-1898. PubMed ID: 37772993
[TBL] [Abstract][Full Text] [Related]
22. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
23. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Yang JC; Xu P; Ning S; Wasielewski LJ; Adomat H; Hwang SH; Morisseau C; Gleave M; Corey E; Gao AC; Lara PN; Evans CP; Hammock BD; Liu C
Oncogene; 2023 Feb; 42(9):693-707. PubMed ID: 36596844
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
[TBL] [Abstract][Full Text] [Related]
26. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
27. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 regulates androgen synthesis in prostate cancer cells.
Chun JY; Nadiminty N; Dutt S; Lou W; Yang JC; Kung HJ; Evans CP; Gao AC
Clin Cancer Res; 2009 Aug; 15(15):4815-22. PubMed ID: 19638459
[TBL] [Abstract][Full Text] [Related]
29. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Tian Y; Zhao L; Zhang H; Liu X; Zhao L; Zhao X; Li Y; Li J
Diagn Pathol; 2014 Feb; 9():42. PubMed ID: 24571686
[TBL] [Abstract][Full Text] [Related]
30. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
32. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
33. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
34. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
35. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
[TBL] [Abstract][Full Text] [Related]
36. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
[TBL] [Abstract][Full Text] [Related]
37. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
39. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
Penning TM
Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
[TBL] [Abstract][Full Text] [Related]
40. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
Tamae D; Mostaghel E; Montgomery B; Nelson PS; Balk SP; Kantoff PW; Taplin ME; Penning TM
Chem Biol Interact; 2015 Jun; 234():332-8. PubMed ID: 25514466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
